Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
J Cardiovasc Dev Dis ; 9(12)2022 Nov 23.
Article in English | MEDLINE | ID: mdl-36547407

ABSTRACT

May Thurner Syndrome contributes to thromboembolic disease and can cause significant morbidity in pregnant patients secondary to exaggerated anatomic relationships and physiologic changes in the hematologic system favoring thrombogenesis. Because this condition is both underrecognized and underreported, management in pregnant and postpartum patients is based on expert opinion without any formal evidence-based guidance. Herein, we review five pregnancies in four patients with May Thurner Syndrome and general management strategies. Through collaborative and multidisciplinary care, patients with May Thurner Syndrome can be safely and successfully managed during pregnancy and the postpartum period with appropriate anticoagulation.

2.
J Vasc Interv Radiol ; 30(9): 1370-1375, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31375449

ABSTRACT

PURPOSE: To report initial experience with safety and efficacy in the treatment of pulmonary embolism (PE) using the FlowTriever device. MATERIALS AND METHODS: A single-center retrospective study was performed in all patients with acute central PE treated using the FlowTriever device between March 2018 and March 2019. A total of 46 patients were identified (massive = 8; submassive = 38), all with right ventricular (RV) strain and 26% with thrombolytic contraindications. Technical success (according to SIR reporting guidelines) and clinical success (defined as mean pulmonary artery pressure intraprocedural improvement) are reported, as are major device and procedure-related complications within 30 days after discharge. RESULTS: Technical success was achieved in 100% of cases (n = 46). Average mean pulmonary artery pressure improved significantly from before to after the procedure for the total population (33.9 ± 8.9 mm Hg before, 27.0 ± 9.0 mm Hg after; P < .0001; 95% confidence interval [CI], 5.0-8.8), submassive cohort (34.7 ± 9.1 mm Hg before, 27.4 ± 9.2 mm Hg after; P < .0001; 95% CI, 5.2-9.5) and massive cohort (30.4 ± 6.9 mm Hg before, 25.4 ± 8.2 mm Hg after; P < .05; 95% CI:0.4-9.6). Intraprocedural reduction in mean pulmonary artery pressure was achieved in 88% (n = 37 of 42). A total of 100% of patients (n = 46 of 46) survived to hospital discharge. In total, 71% of patients (n = 27 of 38) experienced intraprocedural reduction in supplemental oxygen requirements. Two major adverse events (4.6%) included hemoptysis requiring intubation, and procedure-related blood loss requiring transfusion. No delayed procedure-related complications or deaths occurred within 30 days of hospital discharge. CONCLUSIONS: Initial clinical experience using the FlowTriever to perform mechanical thrombectomy showed encouraging trends with respect to safety and efficacy for the treatment of acute central, massive, and submassive pulmonary embolism.


Subject(s)
Pulmonary Artery , Pulmonary Embolism/therapy , Thrombectomy/instrumentation , Acute Disease , Adult , Aged , Aged, 80 and over , Arterial Pressure , Equipment Design , Female , Humans , Male , Middle Aged , Missouri , Oxygen Inhalation Therapy , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/physiopathology , Pulmonary Embolism/diagnostic imaging , Pulmonary Embolism/physiopathology , Retrospective Studies , Thrombectomy/adverse effects , Treatment Outcome
3.
Radiographics ; 39(3): 651-667, 2019.
Article in English | MEDLINE | ID: mdl-30951437

ABSTRACT

Fibrosing mediastinitis is a rare benign but potentially life-threatening process that occurs because of proliferation of fibrotic tissue in the mediastinum. The focal subtype is more common and typically is associated with an abnormal immunologic response to Histoplasma capsulatum infection. Affected patients are typically young at presentation, but a wide age range has been reported, without a predilection for either sex. The diffuse form may be idiopathic or associated with autoimmunity, usually affects middle-aged and/or elderly patients, and is more common in men. For both subtypes, patients present with signs and symptoms related to obstruction or compression of vital mediastinal structures. The most common presenting signs and symptoms are cough, dyspnea, recurrent pneumonia, hemoptysis, and pleuritic chest pain. Patients with the diffuse subtype may have additional extrathoracic symptoms depending on the other organ systems involved. Because symptom severity is variable, treatment should be individualized with therapies tailored to alleviate compression of the affected mediastinal structures. Characteristic imaging features of fibrosing mediastinitis include infiltrative mediastinal soft tissue (with or without calcification) with compression or obstruction of mediastinal vascular structures and/or the aerodigestive tract. When identified in the appropriate clinical setting, these characteristic features allow the radiologist to suggest the diagnosis of fibrosing mediastinitis. Careful assessment is crucial at initial and follow-up imaging for exclusion of underlying malignancy, assessment of disease progression, identification of complications, and evaluation of treatment response. Online supplemental material is available for this article. ©RSNA, 2019.


Subject(s)
Mediastinitis/diagnostic imaging , Multimodal Imaging/methods , Sclerosis/diagnostic imaging , Tomography, X-Ray Computed/methods , Adult , Aged , Aged, 80 and over , Bronchi/diagnostic imaging , Bronchi/pathology , Calcinosis/diagnostic imaging , Calcinosis/etiology , Contrast Media , Diagnosis, Differential , Diagnostic Errors , Female , Granuloma/diagnostic imaging , Granuloma/etiology , Granuloma/pathology , Histoplasmosis/complications , Humans , Male , Mediastinitis/etiology , Middle Aged , Phlebography/methods , Positron Emission Tomography Computed Tomography , Pulmonary Embolism/diagnosis , Radiography, Thoracic/methods , Sclerosis/etiology , Trachea/diagnostic imaging , Trachea/pathology
5.
J Vasc Interv Radiol ; 25(11): 1821-5, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25442143

ABSTRACT

A 54-year-old woman with a symptomatic giant hepatic hemangioma underwent an extended left hepatic trisegmentectomy complicated by 250-350 mL/d postoperative bilious drainage. After 5 months of therapy, drainage was unabated, and the patient was no longer a surgical candidate. Sinography revealed three distinct isolated bile duct leaks involving segments 6, 7, and 8. Endobiliary segmentectomy was achieved by obliterating the isolated systems with ethylene-vinyl alcohol copolymer (Onyx; ev3, Plymouth, Minnesota) during three fluoroscopic procedures. Bilious leaks were successfully eliminated, and compensatory hypertrophy of noninvolved liver occurred. At 2 years from the last embolization procedure, the patient remained asymptomatic with no bilious leak.


Subject(s)
Biliary Tract Diseases/therapy , Embolization, Therapeutic/methods , Hemangioma/surgery , Liver Neoplasms/surgery , Polyvinyls/therapeutic use , Postoperative Complications/therapy , Biliary Tract Diseases/etiology , Cholangiography/methods , Drainage , Female , Hepatectomy/adverse effects , Hepatectomy/methods , Humans , Middle Aged , Postoperative Complications/diagnostic imaging , Tomography, X-Ray Computed/methods , Treatment Outcome
6.
J Vasc Interv Radiol ; 24(9): 1267-72, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23830912

ABSTRACT

PURPOSE: To assess safety and efficacy of intraarterial mechanical thrombectomy for treatment of ischemic stroke in a community hospital by peripheral interventional radiologists employing computed tomography (CT) perfusion imaging for patient selection. MATERIALS AND METHODS: Forty patients, 11 men (27.5%) and 29 women (72.5%), were treated between February 2008 and October 2011. Eligible patients had a National Institutes of Health Stroke Scale (NIHSS) score greater than 8 and diagnosis of large-vessel ischemic stroke by head CT angiogram, and met previously reported CT perfusion imaging triage criteria. RESULTS: The baseline NIHSS score was 18.0 ± 7.9 (range, 8-35). Sixteen patients (40%) had a baseline NIHSS score greater than 20. Symptom onset was unknown in five patients. Symptom onset to device time in the remaining 35 patients was 254.8 minutes ± 150.9 (range, 75-775 min). A total of 65% of patients showed thrombolysis in cerebral infarction (TICI) 2a, 2b, or 3 flow following the procedure. Symptomatic intracranial hemorrhage was seen in four patients (10.0%). At 90 days, 32 patients (80%) were alive and eight (20%) had died. The modified Rankin scale (mRS) score at 90 days was no more than 2 in 20 patients (50.0%). The mean mRS score at 90 days was 2.9 ± 2.0 (range, 0-6). NIHSS score at 90 days was 5.1 ± 6.1 (range, 0-24). In patients with successful recanalization (ie, TICI 2 or 3 flow), a good clinical outcome (ie, mRS score ≤ 2) was achieved in 65.3% of patients (mean, 2.4 ± 1.9; range, 0-6), and 90-day mortality rate was 15.4%, compared with 28.6% in patients with TICI 0/1 flow. CONCLUSIONS: Peripheral interventional radiologists who use CT perfusion imaging for patient triage can have good neurologic outcomes and provide sustainable, safe, and complete around-the-clock coverage for endovascular stroke treatment.


Subject(s)
Brain Ischemia/diagnostic imaging , Brain Ischemia/surgery , Mechanical Thrombolysis/methods , Radiography, Interventional/methods , Stroke/diagnostic imaging , Stroke/surgery , Tomography, X-Ray Computed/methods , Aged , Aged, 80 and over , Brain Ischemia/etiology , Cerebral Angiography/methods , Female , Humans , Male , Mechanical Thrombolysis/adverse effects , Middle Aged , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity , Stroke/etiology , Treatment Outcome , Triage/methods
8.
J Vasc Interv Radiol ; 14(6): 729-33, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12817039

ABSTRACT

PURPOSE: To prospectively assess the feasibility, risk profile, and effect on fibrinogen levels of combination tenecteplase (TNK) and eptifibatide in transcatheter thrombolysis for peripheral arterial and venous thromboocclusive disease. MATERIALS AND METHODS: Sixteen consecutive patients (seven men, nine women) seen at our institution between March and August 2002 with arterial (n = 11) or venous (n = 5) thromboocclusive disease were treated with TNK (5-mg bolus and 0.25-mg/h infusion) and eptifibatide (180- micro g/kg bolus and 1- micro g/kg/min infusion). Informed consent was obtained. Technical success was defined as restoration of antegrade flow and more than 95% removal of thrombus. Clinical success in arterial cases was defined as immediate limb salvage and relief of ischemic rest pain, and in venous cases as resolution or improvement in extremity pain and swelling. Major bleeding was defined as an intracranial bleeding episode, bleeding resulting in death, or bleeding requiring transfusion, surgery, or cessation of thrombolytic therapy. RESULTS: Technical success was achieved in 10 of 11 arterial cases (91%) and in four of five venous cases (80%). Clinical success was achieved in nine of 11 arterial cases (82%) and in four of five venous cases (80%). The mean duration of thrombolysis was 12.1 hours +/- 5.8 (range, 2-22 hours), requiring a total TNK dose of 8.0 mg +/- 1.5 (range, 4.0-10.5). A major bleeding episode occurred in one of 16 patients (6.3%) as a result of slow oozing from a femoral groin access site and required transfusion of 2 U of packed red blood cells. There were no deaths, intracranial hemorrhages, remote sites of bleeding, or minor bleeding complications. The serum fibrinogen level decreased to a mean of 59.3% +/- 34.6 of baseline. CONCLUSION: In this initial study, the combination of TNK and eptifibatide was shown to be feasible for peripheral arterial and venous thrombolysis.


Subject(s)
Arterial Occlusive Diseases/drug therapy , Fibrinolytic Agents/therapeutic use , Lower Extremity/blood supply , Lower Extremity/pathology , Peptides/therapeutic use , Peripheral Vascular Diseases/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Thrombolytic Therapy , Tissue Plasminogen Activator/therapeutic use , Venous Thrombosis/drug therapy , Acute Disease , Adult , Aged , Aged, 80 and over , Arterial Occlusive Diseases/mortality , Biomarkers/blood , Disease-Free Survival , Drug Therapy, Combination , Eptifibatide , Female , Femoral Artery/drug effects , Femoral Artery/pathology , Femoral Vein/drug effects , Femoral Vein/pathology , Fibrinogen/drug effects , Fibrinogen/metabolism , Fibrinolytic Agents/adverse effects , Follow-Up Studies , Hematocrit , Hemoglobins/drug effects , Hemoglobins/metabolism , Hemorrhage/blood , Hemorrhage/chemically induced , Humans , Iliac Artery/drug effects , Iliac Artery/pathology , Iliac Vein/drug effects , Iliac Vein/pathology , Male , Middle Aged , Missouri , Peptides/adverse effects , Peripheral Vascular Diseases/mortality , Pilot Projects , Platelet Aggregation Inhibitors/adverse effects , Popliteal Artery/drug effects , Popliteal Artery/pathology , Popliteal Vein/drug effects , Popliteal Vein/pathology , Prospective Studies , Tenecteplase , Time Factors , Tissue Plasminogen Activator/adverse effects , Treatment Outcome , Vena Cava, Inferior/drug effects , Vena Cava, Inferior/pathology , Venous Thrombosis/mortality
10.
J Vasc Interv Radiol ; 13(11): 1099-102, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12427808

ABSTRACT

PURPOSE: To prospectively assess the feasibility, risk profile, and effect on fibrinogen levels of tenecteplase in transcatheter thrombolysis for peripheral arterial and venous occlusive disease. MATERIALS AND METHODS: Between March 2001 and January 2002, 18 consecutive patients (14 men, four women) with arterial (n = 13) or venous (n = 5) occlusive disease were treated with tenecteplase infusions of 0.25 mg/h. Technical success was defined as restoration of antegrade flow and removal of more than 95% of thrombus. Clinical success was defined in arterial cases as immediate limb salvage and relief of ischemic rest pain and in venous cases as resolution or improvement in extremity pain and swelling. Major bleeding was defined as an intracranial bleeding episode, bleeding that resulted in death, or bleeding that required transfusion, surgery, or cessation of thrombolytic therapy. RESULTS: Technical success was achieved in all 18 patients (100%). Clinical success was achieved in 11 of 13 arterial cases (85%) and in four of five (80%) venous cases. The mean duration of thrombolysis treatment was 21.5 hours +/- 6.2 (range, 7-35 h), with total tenecteplase doses of 7.1 mg +/- 4.3 (range, 1.75-18.75 mg). Major bleeding occurred in one patient (5.5%) because of slow oozing from bilateral femoral groin access sites, which caused a 25% decrease in hematocrit level. There were no deaths, intracranial hemorrhages, remote sites of bleeding, or minor bleeding complications. The serum fibrinogen level dropped to a mean of 77.4% +/- 19.2% of baseline. CONCLUSION: In this initial study, tenecteplase was shown to be a feasible treatment for peripheral arterial and venous thrombolysis with only moderate effect on fibrinogen levels.


Subject(s)
Arterial Occlusive Diseases/drug therapy , Fibrinolytic Agents/therapeutic use , Thrombolytic Therapy , Tissue Plasminogen Activator/therapeutic use , Venous Thrombosis/drug therapy , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Pilot Projects , Prospective Studies , Tenecteplase
11.
J Vasc Interv Radiol ; 13(10): 1037-41, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12397126

ABSTRACT

Traumatic rupture of the thoracic aorta is a common cause of death after vehicle collisions. Associated injuries are common, and patients with lung injury, cardiac contusion, abdominal bleeding, and head injury comprise a group at high risk for conventional surgical or medical therapy. In this particular population, existing commercially available stent-grafts may provide a life-saving repair option. The Ancure and AneuRx stent-grafts, designed for abdominal aortic aneurysm application, were successfully placed in three patients. Accommodation for the short length of the delivery device was achieved by retroperitoneal iliac artery access. All patients had follow-up computed tomography (CT) without evidence of endoleak and were doing well with respect to their chest trauma after 5-9 months of follow-up.


Subject(s)
Aorta, Thoracic/injuries , Blood Vessel Prosthesis Implantation , Stents , Accidents, Traffic , Acute Disease , Aorta, Abdominal , Aorta, Thoracic/diagnostic imaging , Aortic Rupture/etiology , Aortic Rupture/surgery , Child , Female , Humans , Lacerations/etiology , Lacerations/surgery , Male , Middle Aged , Radiography
12.
J Endovasc Ther ; 9 Suppl 2: II84-91, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12166847

ABSTRACT

PURPOSE: To describe the precise anatomical location and extent of injury (based on angiography) in a series of patients with blunt thoracic aortic injury (BTAI) and evaluate the findings relative to the potential for endograft repair. METHODS: Thoracic aortograms from 50 trauma patients (37 men; mean age 37 years, range 13-87) with BTAI were retrospectively reviewed. Parameters important for endograft repair were recorded, including the length of the pseudoaneurysm, the distance between the origin of the most distal arch vessel and the pseudoaneurysm, the diameter of the aorta both above and below the pseudoaneurysm, and finally, the curvature of the aorta in the vicinity of the pseudoaneurysm. RESULTS: The mean distance from the left subclavian artery to the superior aspect of the injury measured 5.8 mm along the lesser curve and 14.9 mm along the greater curve. The mean length of the injury was 17.0 mm and 26.0 mm along the lesser and greater curves, respectively. The mean aortic diameter adjacent to the injury measured 19.3 mm. The mean degree of curvature of the aorta over the length of the injury was 27.2 degrees, with a mean radius of curvature of 32.6 mm at the superior aspect of the injury and 39.3 mm inferiorly. CONCLUSIONS: In most cases of BTAI, the location of the injury will necessitate covering the origin of the left subclavian artery if endovascular repair is to be performed. The curvature of the aorta in the region predisposed to these injuries requires that the endograft be very flexible and/or precurved.


Subject(s)
Aorta, Thoracic/diagnostic imaging , Aorta, Thoracic/injuries , Aortography , Wounds, Nonpenetrating/diagnostic imaging , Adolescent , Adult , Aged , Aged, 80 and over , Blood Vessel Prosthesis Implantation/methods , Female , Humans , Male , Middle Aged , Patient Care Planning , Retrospective Studies , Stents
15.
Radiology ; 222(1): 53-6, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11756704

ABSTRACT

PURPOSE: To evaluate the prevalence of intermittent opacification, a finding previously described as diagnostic of active bleeding that allows identification of an injured vessel at initial aortography or first-order selective angiography. MATERIALS AND METHODS: Retrospective review was performed of 35 consecutive cases that were positive for true or false aneurysm, arteriovenous fistula or malformation, or hemorrhage when a lesion was located beyond a first-order branch of the aorta. An artery that potentially supplied the lesion was considered positive if it filled with contrast material, emptied, and filled again while adjacent vessels demonstrated progressive opacification. RESULTS: Nine (26%) of the 35 cases demonstrated intermittent opacification of an injured artery. All were confirmed as true-positive with superselective catheterization or additional projections, and seven were successfully treated with transcatheter embolization. Intermittent opacification was associated only with false aneurysm and hemorrhage. No congenital arteriovenous malformations or congenital aneurysms demonstrated intermittent opacification. CONCLUSION: If present, the intermittent opacification of an artery is a valuable finding that assists in superselective transcatheter embolization of the arterial branch that supplies a false aneurysm or hemorrhage.


Subject(s)
Aneurysm/diagnostic imaging , Aneurysm/therapy , Angiography/methods , Arteriovenous Malformations/diagnostic imaging , Arteriovenous Malformations/therapy , Adult , Aneurysm, False/diagnostic imaging , Aneurysm, False/therapy , Arteriovenous Fistula/diagnostic imaging , Arteriovenous Fistula/therapy , Contrast Media , Embolization, Therapeutic , Extravasation of Diagnostic and Therapeutic Materials , Female , Hemorrhage/diagnostic imaging , Hemorrhage/therapy , Humans , Male , Retrospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...